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Preoperative chemotherapy for operable breast cancer results in
clinical response rates of 70–90% (Powles et al, 1995; Scholl et al,
1995; Smith et al, 1995; Fisher et al, 1998). However, pathological
complete response (pCR) rates are much lower, usually 5–20%
(Anderson et al, 1991; Bonadonna et al 1993; Smith et al, 1995;
Fisher et al, 1998) and, although it is this small group of patients
that has the best prognosis (Bonadonna et al, 1993; Fisher et al,
1998), there is an overall benefit for this approach because of the
reduced requirement for mastectomy (Powles et al, 1995; Fisher et
al, 1997). However, there are no data that identify at presentation
the patients who will achieve the best outcome for a particular
regimen. Several biological markers have been studied. For
example, Aas reported that for locally advanced disease, treated
with weekly doxorubicin, there was worse outcome for the 17% of
women whose tumours contained a mutation in the L2/L3 domains
of p53 (as detected by pCR) (Aas et al, 1996); whereas Makris
reported that the response to a mitoxantrone-based regimen in
operable breast cancer was not influenced by the level of p53
expression (as determined immunohistochemically) (Makris et al,
1997).
It remains clear, however, that a good response after 3 months’
therapy is associated with better survival (Bonadonna et al, 1993;
Scholl et al, 1996). We have previously reported, the ability of a
mathematical model of tumour response to predict subsequent
regression in locally advanced breast cancer (Cameron et al,
1996). This model allowed for the possibility of a resistant propor-
tion of the tumour in some patients, and we now hypothesize that
this resistance would identify patients with a poorer outcome, due
to similarly resistant micrometastatic disease. Furthermore, the
advantage of this model is that it can detect functional resistance,
as evidenced by the pattern of response, without hypothesizing
the actual mechanism. However, prospective validation of a
prognostic factor requires the use of two independent cohorts of
patients (McGuire, 1991), and we therefore identified a second,
confirmatory group of women with early breast cancer, also
treated with preoperative neo-adjuvant anthracycline-based
chemotherapy.
PATIENTS
A summary of the characteristics of the 44 women with locally
advanced breast cancer and 63 with initially operable disease is
shown in Table 1. All were treated with adriamycin-based neo-
adjuvant chemotherapy. Macroscopic systemic metastases were
excluded by a staging protocol consisting of full blood count,
biochemistry profile, chest X-ray, liver ultrasound scan and bone
scan. Histological confirmation of invasive breast cancer was
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obtained by wedge biopsy of the primary tumour or a palpable
axillary node, from which material was also made available for
determination of the ER concentration by the dextran coated
charcoal (DCC) method.
Patients with locally advanced disease
Defined as women with a clinical staging of T4 N0–2, this group
included the 39 to whom the mathematical model had been previ-
ously applied (Cameron et al 1996), together with a further five
who had completed treatment since that first publication. They
were all treated for 12 weeks with one of two regimens, both based
on weekly doxorubicin at a dose between 20 and 30 mg m–2;
15 patients also received oral cyclophosphamide 150 mg daily for
3 days and infusional 5-fluorouracil at 600 mg m–2 for 24 h (CAF),
whereas the remaining 29 were also given continuous
5-fluorouracil at 200 mg m–2 day–1 (AcF – as in Gabra et al,
(1996)). The majority of patients (25) with a clinical response
underwent loco-regional surgery and all patients received radical
radiotherapy to the breast/chest wall with irradiation of the nodes
only if a surgical clearance had not been performed. All patients
were to receive tamoxifen for 5 years, but in the event six did not
and the data are missing for a further two patients.
Patients with operable breast cancer
A further 63 women were studied, all of whom had presented
with large operable breast cancer (staged clinically as T2 (> 3 cm
diameter) or T3 and N0–1 M0). Forty-three had been treated in a
previously published phase II study of preoperative systemic
therapy (Anderson et al, 1991), whose 10-year survival has been
recently reported (Cameron et al, 1997): 29 women with ER-nega-
tive tumours had primary chemotherapy with four cycles of CHOP
(cyclophosphamide 1 g m–2, doxorubicin 50 mg m–2, vincristine
1.4 mg m–2, to a maximum of 2 mg, and prednisolone 40 mg day–1
for 5 days) administered every 3 weeks, and the remaining 14 were
given the same chemotherapy after a failure of primary endocrine
therapy. A further 20 patients comprised the first patients in the
subsequent randomized trial (Forouhi et al, 1995) to be treated
with preoperative chemotherapy, of whom 14 with ER-negative
tumours had primary chemotherapy (in the same doses but without
the vincristine) and the other six had chemotherapy after failing to
respond to primary endocrine therapy. All patients underwent
subsequent loco-regional surgery, and radiotherapy if breast
conservation had been performed. No postoperative endocrine
therapy was administered.
Tumour measurements
Pre-biopsy clinical tumour measurements were recorded.
Thereafter, while on primary medical treatment, all tumours were
measured at weekly intervals with calipers, and the tumour volume
estimated. For the calculation of the tumour volumes in locally
advanced tumours, two orthogonal tumour diameters, a and b,
were used. The third dimension was estimated as the average of
the other two diameters, and the tumour volume assumed to be an
ellipsoid:
The original clinical protocol for the patients with operable breast
cancer required the estimation of a single average diameter (a)
of the tumour, being determined as the mean of eight caliper
measurements taken at 22.5° axes. In this series of patients, there-
fore, the tumour volume was assumed to be a sphere:
Because of the uncertain effect of haematoma on the tumour diam-
eters recorded, it was felt appropriate to ignore the first 4 weeks’
measurements in any tumour that had had a biopsy (Cameron et al,
1996; Anderson et al, 1991). The only exceptions to this were a
small number (seven) of the operable breast cancers in whom there
was no visible bruising, and in whom, at the time of treatment, it
had been considered valid to record the tumour measurements
from day 1 of chemotherapy.
Clinical tumour response has been assessed using UICC
criteria, but without the confirmatory examination 1 month later,
as all patients underwent surgery and/or radiotherapy on comple-
tion of their 3 months’ chemotherapy, with a pathological CR
(pCR) defined as a tumour with no residual microscopic disease in
the breast or ipsilateral lymph nodes.
MODEL
This has been previously published in detail (Gregory et al, 1990;
Cameron et al, 1996), and therefore only the assumptions under-
lying its design will be reported here. It permits a proportion of the
tumour to be primarily resistant to the therapy, and assumes that
the same proportion of the sensitive cells is killed by each cycle of
chemotherapy (after Skipper, 1978). It assumes that all tumour cell
growth is exponential, with no difference in the growth rates of the
sensitive and resistant cells. Using the method of maximum likeli-
hood, it optimizes the fit of the predicted tumour volumes to the
actual tumour volumes by repeated iteration, until no further
improvement in the fit can be obtained (see Appendix). Thus,
Table 1 Patient data
Locally advanced
Inflammatory 20 (45%)
Non-Inflammatory 24 (55%)
ER + ve 19 (43%)
ER – ve 23 (52%)
ER U/K 2 (5%)
Post-chemotherapy pathological node status:
Axillary node involvement 15 (34%)
Axillary node negative 8 (18%)
Axillary nodes unknown 21 (48%)
Operable
T2 35 (56%)
T3 28 (44%)
ER + ve 12 (19%)
ER – ve 51 (81%)
Prior hormone therapy 20 (32%)
No prior therapy 43 (68%)
Post-chemotherapy pathological node status:
Axillary node involvement 26 (41%)
Axillary node negative 37 (59%)
p´[a ´ b ´ (a + b)/2] p´a ´ b ´ (a + b)
Tumour volume »=
61 2
p´a3
Tumour volume »
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using the individual pretreatment tumour volumes, and the same
initial values for the resistant proportion, cell-kill and tumour
growth-rate, the clinical tumour volumes for these parameter
values are calculated. These predicted volumes (Vi) are compared
to those recorded at times (ti) for the patient during treatment:
where the suffix ‘i’ denotes the cycle number. The values of the
initial volume (Vo) cell-kill (k), resistant proportion (R) and tumour
growth rate (a) were then adjusted to minimize the difference
between the actual and predicted tumour volumes, assuming, in
recognition of the fact that clinical measurements of tumour
volume are prone to error, a log-normal distribution for these
errors (see Appendix). In many instances the best-fit occurred with
very low values of a, and in these cases a minimum value of
0.000007 was assumed (corresponding to a doubling time of
10 000 days). This was done in order to avoid computational
problems that would be caused by a zero value of a.
The hypothesis under consideration was that a worse outcome
would be associated with incomplete tumour cell-kill, as a conse-
quence of either a low cell-kill or a significant proportion of the
tumour being resistant to the therapy. Since the derivation of both
parameters depends on the pattern of tumour response to a cycle of
chemotherapy, it was felt important to run the model over the same
number (four) of cycles of chemotherapy in both groups of
tumours. Thus, for the locally advanced tumours this was the first
4 weeks’ therapy for 21 tumours, and the second 4 weeks in the
remaining 23 (who had undergone an initial tumour biopsy).
However, in the case of the operable tumours, since the
chemotherapy was administered every 3 weeks for 12 weeks, the
first four cycles therefore included all the recordings up to the time
of loco-regional surgery (excluding those taken from the time of
biopsy until day 28 in all but seven patients – see above).
Regression line analysis
It has previously been proposed (Thomlinson, 1982; 1987) that the
effect of treatment can be assessed by looking at the regression of
the (log of) tumour volume with time. This approach had been
employed by Anderson et al (1991) in their study of neo-adjuvant
systemic therapy in operable breast cancer and was thereforealso
considered for all the patients in this current study, including the
40 patients with operable disease in Anderson’s original series.
The regression lines were produced using Minitab, and only
considered significant when P < 0.05.
Statistics
Comparisons of cell-kill were made using the student t-test,
whereas the Mann–Whitney test was used for resistance and
doubling times as their distribution was not normal (or log-
normal). Minitab version 12.1 was used for both tests. The 
log-rank test was used for comparing the survival of different
groups of patients. In assessing putative prognostic factors for
survival, the cut-points were optimized in the group of locally
advanced tumours, and then the same cut-point applied to the
patients with operable cancers.
RESULTS
Clinical response
The overall response rate for the patients with locally advanced
disease was 32/44 (73%), with two pathological complete
responses (pCR) out of the 18 patients who underwent post-
chemotherapy surgery, giving a confirmed pCR rate of 5% for the
group as a whole. One patient progressed during treatment, and
proceeded directly to radiotherapy. The remaining 25 patients did
not undergo surgery, usually because the tumour was still con-
sidered inoperable. For the patients with operable breast cancer the
response rate was 50/63 (79%), including eight (13%) patients
with pCR. No patient with operable breast cancer progressed
during primary chemotherapy.
Overall survival
The overall survival for both groups of patients is shown in
Figure 1, where it can be seen that the median survival is 3.7 years
for those presenting with locally advanced disease, but has not yet
been reached for those patients with operable breast cancer.
Survival in relationship to response
There were no differences in survival for the patients with locally
advanced disease according to their clinical response to therapy
(data not shown). Neither of the patients with a pathological
complete response have died, but this is not a significant difference
from the remaining patients. The women with operable breast
cancer who had a response to primary therapy had a better prog-
nosis (CR/PR vs SD/PD; P < 0.001) as did those with lesser
degrees of axillary lymph node involvement (P < 0.001) (data not
shown) consistent with prior observations for these patients
(Cameron et al, 1997).
Regression line analysis of response
All but one of the locally advanced tumours had a significant
regression line of the log of the volume against time, with a
median gradient of –0.030 (range –0.102 to +0.025). There were
two patients with positive gradients: one progressed and the other
had stable disease. The remaining 42 were all negative. However,
there was no correlation between the actual gradient and either
clinical response or patient survival. In contrast, for the patients
presenting with operable breast cancer 11/63 (17%) had non-
significant regression lines, and for the remaining 52, the median
gradient was –0.268 (range –0.058 to –0.843). Those patients with
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Figure 1 Overall survival curve for patients with locally advanced
(n = 37) and operable (n = 63) breast cancerResponse modelling of breast cancer 101
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steeper regression lines (gradient < –0.30) had significantly better
survival (c2 = 4.34; P < 0.05).
Model parameters
As previously reported, seven women with locally advanced
breast cancer had either inadequate tumour measurements (n = 3)
or apparent initial tumour growth with a later response (n = 4),
such that the model could not be applied. Thus, there were 37
women for whom model parameter data are available, and all
subsequent analyses have been confined to these women.
However, the survival of the seven women excluded was no
different from that of the 37 women to whose data the model was
successfully applied, and none of these women had a complete
pathological response. The model was successfully applied to all
the operable breast cancers.
The model parameters for all patients are shown in Table 2,
where they have been categorized by clinical and pathological
tumour response, showing the mean/median values for the two
groups of tumours both together and separately. There were
significant differences in tumour model parameters for patients
according to their clinical and pathological responses. The 10
patients with a pCR had significantly higher mean value for
k (P < 0.002) than those without. All of them had zero values of R,
which is significantly different from those patients without a pCR
(c2 = 5.91, P < 0.02). For the 21 patients with a clinical complete
response, all but one had a zero value of R, which together with the
mean value of k was significantly different (P < 0.0005), as compared
with those tumours that failed to achieve a CR. When considering
all responding tumours, there were significant trends for higher
values of k, and lower values of R and a (P < 0.07, P < 0.02 and
P < 0.002, respectively) in comparison to those tumours that did
not respond. The 37 tumours found to be node-negative at the time
of definitive surgery had an average k value of 0.607, significantly
higher than the average value of 0.487 for the 44 tumours with
involved axillary nodes (P < 0.05). Similarly, the 66 ER-negative
tumours had an average value of 0.569, significantly higher than
the value of 0.437 for the 29 ER-positive tumours (P < 0.05).
There were no significant differences in the values of R and a
between ER-positive and ER-negative tumours or between the
node-negative and node-positive tumours.
These same trends are in general still seen when considering the
operable breast cancers alone, but in the group of locally advanced
tumours, they were not significant. This may be due to the diffi-
culty in precise measurements in locally advanced tumours.
Contrasting the parameters derived for the two groups of patients,
the mean value of k (per drug administration) was highly signifi-
cantly lower for the weekly regimen (P < 0.00001) with no
significant differences seen in the values of R or  a. Figure 2
illustrates an operable breast cancer in which the model detected a
Table 2 Model parameters by clinical response
Model estimated parameter values
Response Number k R 0.6903/a
cell-kill resistance doubling timea
(mean) (median) (% non-zero) (median in days)
Locally advanced tumours
pCR 2 0.250 0.0 0% 10 000
CR 8 0.392 0.0 13% 10 000
PR 17 0.288 0.0 35% 10 000
SD/PD 8 0.322 0.0 25% 10 000
(Plus U/K 2)
trend analysis n.s. n.s. n.s.
Operable tumours
pCR 8 0.909 0.0 0% 10 000
CR 13 0.750 0.0 0% 10 000
PR 29 0.554 0.081 55% 10 000
SD 13 0.473 0.197 69% 211
Trend analysis P < 0.00001 P < 0.0002 P < 0.05
All patients
pCR 10 0.777 0.0 0% 10 000
CR 21 0.613 0.0 5% 10 000
PR 46 0.458 0.0 48% 10 000
SD/PD 21 0.415 0.07 52% 10 000
Trend analysis P < 0.005 P < 0.0001 n.s.
(for 98 with known response)
aMaximum doubling time permitted by model was 10 000 days.
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Figure 2 An example of a tumour with significant re-growth during
chemotherapy, illustrating the growing resistant cell population
(cell-kill = 0.595, resistance = 0.26 and doubling time is 69 days)102 DA Cameron et al
British Journal of Cancer (2000) 83(1), 98–103 © 2000 Cancer Research Campaign
non-zero value of R and a high value for a. The inexorable growth
of the underlying resistant fraction is also shown.
Survival in relationship to model parameters R, k, a
For the parameter R, Figure 3 shows the optimum separation of
survival curves for the patients with locally advanced tumours,
with a poorer outcome for those patients with values of R > 0.08,
corresponding to 8% of the tumour being resistant (P < 0.01). The
survival curves for this same cut-point applied to the patients with
operable disease is shown in Figure 4, and again the patients with
higher values had a worse outcome (P < 0.05). No consistent
differences could be found for the two groups of patients
according to the values of k or a (data not shown).
DISCUSSION
Given that no single biological marker appears to predict outcome
with preoperative chemotherapy, this study was designed to assess
the ability of a mathematical model of tumour response to identify
patients with differing prognoses, hypothesizing that an in vivo esti-
mate of tumour resistance might predict for a poorer outcome. Being
applied to tumour volumes during therapy, it derives three parame-
ters, k, R, and a (given respectively the names of cell-kill, resistance
and tumour growth rate). Current scientific knowledge does not
permit the accurate biological measurement of these facets of a
tumour, and therefore the numbers derived by the model must first
be assessed in terms of whether they are internally consistent with
what would be expected from their designated names.
Lower values of R are seen in responding tumours, with, more
importantly, all the tumours with a pCR having zero values.
Indeed, of all the tumours with a CR and/or pCR, only one had a
non-zero value, and the tumour measurement on week 4 was tran-
siently larger than the preceding week, with a zero value being
found if the volume from week 5 was also included, suggesting
that the measurements on week 4 were erroneous. Similarly,
higher values of k were found in tumours with pathological and/or
clinical CR as opposed to those without, consistent with more cell-
kill occurring in tumours with the best response to therapy.
Furthermore, ER-negative tumours had higher values of k, consis-
tent with studies showing that such tumours respond better to
chemotherapy than ER-positive tumours (Mauriac et al, 1991;
Bonadonna et al, 1990; Bélembaogo et al, 1992). Comparing the
values of k for the two groups of patients, the average value in the
operable breast cancers (treated with a 3-weekly regimen) was
significantly higher, consistent with a degree of dose-response. In
contrast to k and R, the only significant correlation found for the
parameter  a was between responding and non-responding
tumours, suggesting that for at least some tumours the lack of
response to therapy may be a consequence of re-growth rather than
just inadequate cell-kill. Since the model is set to detect the growth
rate during chemotherapy (which is not necessarily equivalent to
the growth rate off treatment), any tumour that had detectable re-
growth between cycles, as is seen for example in Figure 4, would
be more likely to have a higher value of a, representing a shorter
doubling time. Consistent with this is the observation that none of
the 10 patients in pCR had a doubling time below the artificial
maximum of 10 000 days. However, the majority of the tumours
studied were found to have the maximum doubling time, and the
model is not sensitive to the detection of tumour growth, since it
can be run with all tumours proliferating with the maximum
doubling time without changing any of the conclusions reported.
Returning now to the original hypothesis, namely that drug
resistance manifest in the primary tumour response would be
associated with a poorer survival, it can be seen in Figure 3 that
patients with locally advanced tumours having R > 0.08 had a
significantly poorer survival. The prognostic importance of this is
confirmed in the independent series of patients with early breast
cancer, as shown in Figure 4, suggesting that this parameter repre-
sents resistance of the cancer to systemic therapy. Although the
more traditional clinical definition of response did predict for the
outcome of patients with operable breast cancer, irrespective of
whether it was assessed by a regression line or simple UICC
criteria, this was not the case for the locally advanced tumours. In
contrast, for both groups of patients, the parameter R does appear
to represent clinical resistance of both the primary tumour and sub-
clinical metastatic disease. The model as applied to the patients
with operable breast cancer given every 3 weeks required tumour
measurements over a 12-week period of treatment, offering no
obvious advantage to assessing clinical and pathological response
at the completion of the chemotherapy, and using these more tradi-
tional measures of response on which to base any change of
therapy. However, with weekly chemotherapy, the model data are
available after 4 weeks’ therapy, and therefore this approach could
be used to identify earlier patients with both a poor response and
its associated worse outcome.
How does the pattern of tumour response produce the parameter
‘resistance’ in a manner that determines patient outcome? Figure 2
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Figure 3 Survival by model-estimated resistance for patients with locally
advanced breast cancer; above (n = 8) and below 8% (n = 29) (c2 = 8.574,
P = 0.003)
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Figure 4 Survival by model-estimated resistance for patients with large
operable breast cancer; above (n = 17) and below 8% (n = 46) (c2 = 4.84,
P = 0.028)Response modelling of breast cancer 103
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demonstrates that the presence of a significant proportion of resis-
tant tumour results in a plateau in the tumour response curve, and
when present, it is this which is detected by the model as R, the
resistance parameter. The survival data shown in Figures 3 and 4
suggest that the lack of on-going tumour response is paralleled by
a similar failure of cell-kill in any micro-metastatic disease. Other,
linear regression, approaches to modelling tumour volumes, such
as proposed by Thomlinson (1982; 1987) cannot detect such a
plateau, and when applied to the tumours studied here, provided
neither such a good fit to the tumour volumes (data not shown),
nor any consistent prognostic information (see above). The data
suggest that survival is determined only by the resistant fraction
of the tumour, whereas tumour response relates to all three para-
meters k, R, a. Further validation of the model would occur if
significant correlations were to be found between these parameters
and biological markers of cell-proliferation, cell-kill and resis-
tance. Such studies are underway, but whatever their conclusions,
the true relevance of the parameters would be best demonstrated
by a prospective study assessing the ability of this approach to
identify poorly responding tumours early in their course of treat-
ment, and testing the ability of alternative (non-cross-resistant)
therapies to overcome the manifest drug resistance.
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Appendix
Let V0 be the initial tumour volume. Then, assuming that the same
proportion  k of tumour cells are killed by each cycle of
chemotherapy, and that the whole tumour grows with constant
exponential growth rate a, it can be shown that the volume V1 at
the time t1 of the next tumour measurement is given by the
following equation:
V1 = (1 – k (1 – R)) V0 exp (at1)
where  R is the (fixed) resistant proportion of the tumour. In
general, the volume Vi at time ti will depend on whether or not
treatment was given at the previous time-point ti–1. If treatment
was given, then the new volume is given by the following
equation:
Vi = (1 – k (1 – R)) Vi–1 exp (a(ti – ti–1))
whereas for two successive time points where tumour measure-
ments have been recorded without any intervening treatment, the
equation reduces to:
Vi = Vi–1 exp(a(ti – ti–1))
In order to get the best model prediction of the actual volumes Ai,
the values of the parameters k, a, R, and V0 need to be adjusted.
Since a log-normal error distribution has been assumed for the
errors in the tumour measurements, using the method of maximum
likelihood, it can be shown that the problem is to maximize:
P
i=n
i = 0 N(log Ai, log Vi, s)
where N(Ai, Vi, s) is the value of a normal distribution, whose
mean is given by the model-predicted volume Vi, and standard
deviation s. This maximization was done iteratively, using a
semi-Newtonian algorithm and the first partial derivatives with
respect to each parameter.
REFERENCES
Aas, Børresen, Geisler, Smith-Sørensen, Johnsen, Varhaug, Akslen and Lønning
(1996) Specific p53 mutations are associated with de novo resistance to
doxorubicin in breast cancer patients. Nature Medicine 2: 811–814
Anderson, Forrest, Hawkins, Anderson, Leonard and Chetty (1991) Primary
systemic therapy for operable breast cancer. British Journal of Cancer 63:
561–566
Bélembaogo, Feillel, Chollet, Curé, Verrelle, Kwiatkowski, Achard, Le Bouëdec,
Chassagne, Bignon, De Latour, Lafaye and Dauplat (1992) Neoadjuvant
chemotherapy in 126 operable breast cancers. Eur J Cancer 28A: 896–900
Bonadonna, Valagussa, Brambilla and Ferrari (1993) Preoperative chemotherapy in
operable breast cancer. Lancet 341: 1485–1485
Bonadonna, Veronesi, Brambilla, Ferrari, Luini, Greco, Bartoli, Coopmans De Yoldi,
Zucali, Rilke, Andreola, Silvestrini, Di Fronzo and Valagussa (1990) Primary
chemotherapy to avoid mastectomy in tumours with diameters of three
centimetres or more. Journal of the National Cancer Institute 82: 1539–1545
Cameron, Anderson, Levack, Hawkins, Anderson, Leonard, Forrest and Chetty
(1997) Primary systemic therapy for operable breast cancer – 10-year survival
data following chemotherapy and hormone therapy. Br J Cancer 76:
1099–1105
Cameron, Gregory, Bowman and Leonard (1996) Mathematical modelling of tumour
response in primary breast cancer. Br J Cancer 73: 1409–1416
Fisher, Brown, Mamounas, Wieand, Robidoux, Margolese, Cruz, Fisher,
Wickerham, Wolmark, Decillis, Hoehn, Lees and Dimitrov (1997) Effect of
preoperative chemotherapy on local-regional disease in women with operable
breast cancer: findings from National Surgical Adjuvant Breast and Bowel
Project B-18 [see comments]. Journal of Clinical Oncology 15: 2483–2493
Fisher, Bryant, Wolmark, Mamounas, Brown, Fisher, Wickerham, Begovic, Decillis,
Robidoux, Margolese, Cruz, Jr, Hoehn, Lees, Dimitrov and Bear (1998) Effect
of preoperative chemotherapy on the outcome of women with operable breast
cancer. Journal of Clinical Oncology 16: 2672–2685
Forouhi, Dixon, Leonard and Chetty (1995) Prospective randomized study of
surgical morbidity following primary systemic therapy for breast-cancer.
Br J Surgery 82: 79–82
Gabra, Cameron, Lee, Mackay and Leonard (1996) Weekly doxorubicin and
continuous infusional 5-FU for advanced breast cancer. Br J Cancer 74:
2008–2012
Gregory, Reznek, Hallet and Slevin (1990) Using mathematical models to estimate
drug resistance and treatment efficacy via CT scan measurements of tumour
volume. Br J Cancer 62: 671–675
Makris, Powles, Dowsett, Osborne, Trott, Fernando, Ashley, Ormerod, Titley,
Gregory and Allred (1997) Prediction of response to neoadjuvant
chemoendocrine therapy in primary breast carcinomas. Clinical Cancer
Research 3: 593–600.
Mauriac, Durand, Avril and Dilhuydy (1991) Effects of primary chemotherapy in
conservative treatment of breast cancer patients with operable tumours larger
than 3 cm. Annals of Oncology 2: 347–354
McGuire (1991) Breast cancer prognostic factors: evaluation guidelines. J Natl
Cancer Inst 83: 154–155
Powles, Hickish, Makris, Ashley, O’Brien, Tidy, Casey, Nash, Sacks, Cosgrove,
Macvicar, Fernando and Ford (1995) Randomized trial of chemoendocrine
therapy started before or after surgery for treatment of primary breast cancer.
Journal of Clinical Oncology 13: 547–552
Scholl, Asselain, Beuzeboc, Pierga, Dorval, Garcia-Giralt, Jouve, Palangié,
Fourquet, Durand and Pouillart (1995) Neoadjuvant versus adjuvant
chemotherapy in premenopausal patients with tumours considered too large for
conserving surgery: an update. Anti-Cancer Drugs 6 (Suppl 2): 69 (abstract
P48)
Scholl, Pierga, Asselain, Buezeboc, Dorval, Garcia-Giralt, Jouve, Palangié,
Remvikos, Durand, Fourquet and Pouillart (1996) Breast tumour response to
primary chemotherapy predicts local and distant control as well as survival.
Eur J Cancer 31A: 1969–1975
Skipper (1978) Reasons for Success and Failure in the Treatment of Murine
Leukemias with the Drugs Now Employed in Treating Human Leukemias, Vol
1. University Microfilms International: Ann Arbor
Smith, Walsh, Jones, Prendiville, Johnston, Gusterton, Ramage, Robertshaw, Sacks,
Ebbs, Mckinna and Baum (1995) High complete remission rates with primary
neoadjuvant infusional chemotherapy for large early breast cancer. Journal of
Clinical Oncology 13: 424–429
Thomlinson (1982) Measurement and management of carcinoma of the breast.
Clinical Radiology 33: 481–493
Thomlinson (1987) Cancer: the failure of treatment. British Journal of Radiology 60:
735–751 